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Abstract
Selective progesterone receptor modulators (SPRM) represent a new class of synthetic steroids, which can interact with the
progesterone receptor (PR) and can exert agonist, antagonist or mixed effects on various progesterone target tissues in vivo.
This review evaluates the actual and potential usefulness of SPRMs in gynaecology.
Keywords: ???AL
Introduction
The progesterone receptor (PR) belongs to the
nuclear receptor super family and controls specific
genes involved in female reproduction. The primary
action of progesterone is to initiate and maintain
pregnancy. Progesterone, the natural ligand of the PR,
represents the pure agonist, onapristone, mifepristone
show a pure antagonist activity and asoprisnil exhibits
partial agonist/antagonist effects [1].The synthesis of
mifepristone, the first PR antagonist (PA) was a
starting point of drug discovery and the research
programme in the area of PAs [2–4].
Progesterone is involved in the control of ovulation,
facilitating the luteinising hormone (LH) surge.
It transforms the endometrium from a proliferative
to a secretory state and, together with estradiol,
maintains endometrial integrity [5] preparing the
endometrium for implantation. It inhibits uterine
contractility [6].
In uterus, progesterone controls the growth and
differentiation of endometrial and myometrial cells.
During the luteal phase, in the primate uterus,
progesterone inhibits estrogen induced mitotic activ-
ity in the functional zones of the endometrial
epithelium but shows some stimulatory effect on both
the basalis and endometrial angiogenesis [7]. Proges-
terone can also play a key role on growth of benign
smooth muscles tumours from uterine myometrium
[8–10]. In normal breast epithelial cells, progesterone
has important mitogenic properties with a peak of a
mitotic activity during the luteal phase [11].
Synthetic progestins administered with estrogen
in post-menopausal women are involved in the
moderately increased risk of breast cancer [12,13].
In the mammary glands of nulliparous Brca1/p53
deficient mice, the PA mifepristone prevents
mammary tumorigenesis [14].
From the physiological properties of progesterone
and the pharmacological profile of synthetic proges-
tins, and their possible drawbacks, it appears that the
potential advantages and the clinical applications of
selective progesterone receptor modulators (SPRMs)
are very promising in major public health areas.
Clinical application of the SPRMs
Medical abortion
Mifepristone, the first glucocorticoids, and PA [2], a
derivative of norethindrone, alters the endometrium
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separate from decidua [2,15–17]. Mifepristone sen-
sitises the pregnant uterus and cervix to endogenous
and exogenous prostaglandins, increasing uterine
activity and inducing cervical softening. Mifepristone
is well absorbed orally and reaches a peak serum
concentration in pregnant woman within 2 hours.
The pharmacokinetics is similar for any dose over
100 mg. The half-life of mifepristone is approxi-
mately 19 hours in pregnant women [16].
Mifepristone used alone with oral doses ranging
from 50 to 400 mg allows complete abortion in 60–
80% up to 48 days gestation. The addition of small
doses of a prostaglandin analogue (such as mis-
oprostol) has a synergistic effect resulting in nearly
100% complete abortion [18,19] with lower doses
than those required when the prostaglandin analogue
is used alone. Moreover, the addition of mifepristone
to misoprostol increases complete abortion at a faster
rate up to 63 days gestation [16].
The most commonly used medical abortion
regimen worldwide is presently mifepristone fol-
lowed by a prostaglandin analogue. The FDA-
approved regimen consists of 600 mg of oral
mifepristone followed by a prostaglandin analogue,
usually misoprostol, 36–48 hours later. This regi-
men has been reported to induce complete abortion
in 92–99% women [20–23]. As expected on the basis
of its pharmacokinetics, lower doses of mifepristone
are equally effective as the 600 mg dose when
combined with a prostaglandin analogue [24–26].
In the large trial performed by the World Health
Organisation, pregnant women were included up to
63 days gestation and received either 200 mg or
600 mg mifepristone, followed 48 hours later by an
oral administration of 400 mg misoprostol. Both
groups showed similar complete abortion rates (89
and 88%, respectively) [26]. This efficacy is similar
to that of vacuum aspiration. In addition, studies
using 200 mg mifepristone combined with 800 mg
misoprostol administered vaginally to more than
4000 women also confirmed the efficacy of this low
dose of mifepristone [27–29]. The vaginal adminis-
tration of misoprostol prolongs the efficacy of
mifepristone regimens up to 63 days. A shorter
interval between the administration of mifepristone
and prostaglandin analogue does not impair the rate
of abortion [30].
The use of mifepristone between 9 and 13 weeks
gestation is equally effective as a cervical primer [31].
Animal studies showed that mifepristone induces
collagen remodelling. It caused a decrease in
collagen organisation with decreased fibril length
and diameter [32]. The prostaglandin analogue,
misoprostol, is more commonly used in this indica-
tion because it is cheaper and largely available.
Nevertheless, bleeding and abdominal pain are
decreased with mifepristone compared with miso-
prostol [31,33].
Mifepristone for second trimester abortion de-
creases the interval between induction to abortion
and increases the success rate. It is administered in
either 200 or 600 mg dosing and followed by
prostaglandin analogue.
Management of miscarriage
A randomised placebo controlled trial showed that
expulsion occurred in 82% of women with first
trimester arrested pregnancy, within 5 days after
administration of 600 mg mifepristone compared
with only 8% of women given placebo but the success
rate was comparable with that of a misoprostol used
alone [34].
Emergency contraception
Emergency contraception (EC) is a term used to
describe a group of methods for preventing an
unwanted pregnancy that are administered during
the first few days after unprotected intercourse. It can
decrease individual woman’s pregnancy risks by as
much as 89% after a single coitus. EC is an important
action for woman giving them a chance to avoid the
psychological and physical consequences of un-
wanted pregnancy including the need for legal or
clandestine abortion [35].
Several approaches to EC have been described,
including high doses of estrogens, danazol, intra-
uterine devices, oral contraceptive with estrogen and
progestin [36], a progestin alone (levonorgestrel)
and SPRMs (mifepristone and VA 2914). The
Yuzpe regimen involved the combined use of
ethinyl estradiol 100 mg and 0.5 mg of levonorges-
trel, repeated once 12 hours apart, with the first
dose given within 72 hours of unprotected inter-
course. This regimen, which was popular in the late
seventies and early eighties, has now been sup-
planted by a more effective and better tolerated
progestin only product, containing levonorgestrel.
They were to be used within 72 hours of unpro-
tected inter-course.
PR modulators offer another option for EC. They
can maintain efficacy for periods of time, longer than
72 hours in a single dose regimen [37,38]. A higher
efficacy of mifepristone compared with the Yuzpe
regimen was also observed. Side effects such as
nausea, vomiting, headache, dizziness, fatigue, low
abdominal pain and hot flushes were observed less
frequently in women receiving mifepristone [39].
Lowering the dose of mifepristone from 600 to
10 mg did not significantly impair its effectiveness as
an emergency contraceptive [40]. Low doses of
mifepristone are associated with less disturbance of
the menstrual cycle length. A dose as low as 10 mg
seems preferable to the 600 mg dose [38]. This trial
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regimen, the efficacy of mifepristone does not appear
to decline with increased interval up to 120 h.
Recently, a second generation PR modulator
with lower anti-glucocorticoid activity than mife-
pristone was tested in EC. Participants were
randomly assigned to receive a single dose of
50 mg of VA 2914 plus a placebo 12 hours later or
two doses of 0.75 mg of levonorgestrel taken 12
hours apart. VA 2914 was at least as effective as
levonorgestrel in preventing pregnancy after un-
protected intercourse. Lower efficacy with increas-
ing interval between intercourse and EC treatment
above 48 hours was observed only with levonor-
gestrel. In contrast, the effectiveness of VA 2914
did not decline after 48 hours. Adverse effects were
generally similar in both treatment groups, but
more nausea was observed among the VA 2914
treated women. Nausea, as a side effect, has not
been reported in other trials with VA 2914 at
higher doses. Moreover, VA 2914 was also effective
in preventing pregnancy when administered after
ovulation [36]. In both groups, women experienced
considerable variation in menstrual cycle length
when compared with their reported individual
normal cycle length. On average, the onset of
menses after EC use was 2, 1 day earlier than
anticipated in levonorgestrel users and 2, 6 days
later in VA 2914 users [37].
Acceleration of tubal transport of fertilised eggs
has been reported in rats exposed to anti-progestogen
[41]. No information is available in women. It is well
documented, however, that mifepristone does not
increase the risk of tubal pregnancy [41,42].
Long-term contraception
PAs and SPRMs do have contraceptive potential
possibly, by several mechanisms [5,43]. They inhibit
ovulation by blocking the LH surge and can induce
endometrial desynchronisation, thereby interfering
with implantation. Recently, mifepristone but not
levonorgestrel was shown to inhibit human blastocyst
attachment to an in vitro endometrial three-dimen-
sional cell culture model [44]. High doses of
mifepristone may even induce follicular atresia [45].
The threshold dose for ovulation inhibition is
2 mg/day. At a lower dosage, ovulation occurs and
the administration of 0.5 mg mifepristone daily or
5 mg weekly is not effective in pregnancy prevention
[46,47]. Two-hundred milligrams of mifepristone,
administered 48 hours after the LH surge, shows
contraceptive efficacy. However, this option is not
clinically relevant because the detection of an LH
surge routinely is an expensive and an unreliable
method [5,47].
Administration of mifepristone, in the late luteal
phase, is not effective in pregnancy prevention
[48,49].
VA 2914 is an orally active steroidal SPRM which
demonstrates potent PA activity in vivo and in vitro
[50] with a reduced anti-glucocorticoid activity
compared with mifepristone [51]. This compound
shows anti-ovulatory activity and post-coı¨tal anti-
fertility activity in rats [52].
We evaluated ovulation inhibition by VA 2914 in
women, in a continuous regimen of administration of
2.5, 5 and 10 mg/day for 3 months. We also
examined the endometrial impact in each group.
Anovulation (defined by absence of progesterone
above 3 ng/mL) was obtained in nearly 80% women
in the 5 and 10 mg/day groups with a high rate of
amenorrhea (81.2 and 90%, respectively). Plasma
estradiol levels remained in the physiological folli-
cular phase range.
Endometrial histological analysis showed pre-
dominantly a pattern of secretory phase. Some cystic
glandular dilatations were observed in rare cases. No
hyperplasia was detected [53].
We quantified the effects of VA 2914 on endo-
metrial vascularisation, fibrillar matrix and vascular
endothelial growth factor (VEGF)-A expression in
endometrial biopsies from 41 women before and
after 12 weeks treatment. No changes were noted in
structure, number and size of endometrial vessels.
The collagen network and VEGF-A distribution
remained comparable during the luteal phase at
baseline and under VA 2914 treatment [54]. From
these observations, we conclude that long-term VA
2914 treatment does not result in an endometrial
morphology comparable with that induced by a
progestin. It thus acts on endometrial cells, in a
specific way, which is clearly distinct from that of
a progestin.
Treatment of uterine leiomyomata
Uterine leiomyomata, also named fibroids, are
benign tumours that occur in up of 35% women
above 35 years. They account for up to 40% of all
hysterectomies [55]. Non-surgical treatment options
for symptomatic leiomyomata are limited because
gonadotropin releasing hormone agonists (GnRHa)
induce hypo estrogenism and side effects limiting the
treatment duration [56]. Even, when a decrease in
leiomyomata size of 36% is observed after 12 weeks
of GnRHa treatment, the uterus returns to pre-
treatment size within 6 months after treatment
completion. The indications of GnRHa are thus
limited to short-term pre-surgical treatment [57].
Progesterone and PR seem to play a key role in the
control of uterine fibroid growth [58]. Mitotic
activity is maximal during the luteal phase [59].
Several studies have shown an up-regulation of PR in
uterine leiomyomata compared with normal adjacent
myometrium at mRNA and protein levels [60]. The
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increased in leiomyomata, when compared with that
in normal myometrium, and up-regulated by pro-
gesterone [60]. Expression of epidermal growth
factor, a proliferative cytokine, and Bcl2, an apoptosis-
inhibiting protein is also increased in fibroids
relative to the adjacent myometrium, specifically
during the secretory phase [61]. Progesterone in-
creases Bcl2 protein expression in primary leiomyo-
mata cell cultures [62]. Progestins finally attenuate or
even reverse the inhibitory effects of GnRHa on
leiomyomata size when used as add-back therapy
[63–65]5 . However, Mifepristone has opposite effects
[66] and may decrease proliferation of these smooth
muscle cells, suggesting a clinical usefulness of
SPRMs for the treatment of myomas. Asoprisnil,
a mixed progesterone agonist/PA with no anti-
glucocorticoid effect, inhibits proliferation and
induces apoptosis in cultured uterine leiomyoma
cells in the absence of comparable effects on cultured
normal myometrial cells suggesting a cell type
specific effect [67].
Down regulation of VEGF, of adrenomedullin, a
vasoactive hormone and of their receptors was shown
by western blot analysis in cultured human uterine
leiomyoma cells treated with VA 2914. This action of
VA 2914 was not observed in the surrounding
normal myometrial cells, suggesting a cell type
specific action of this SPRM on leiomyoma cells
[68].
In clinical studies, daily treatment with 5–50 mg
mifepristone for 3–6 months resulted in a reduction
in uterus and leiomyoma volumes, ranging from 27
to 49% and 26 to 74%, respectively. Moreover, the
prevalence and severity of dysmenorrhoea, meno-
rrhagia and pelvis pressure were reduced. Treatment
was well tolerated. Nevertheless, endometrial hyper-
plasia, a serious adverse effect of mifepristone was
detected in 28% women [65]. A 20% reduction of
myoma volume was also observed in over 90%
patients treated with 12.5 mg mifepristone or
GnRHa [69]. The recurrence rate after cessation of
treatment was 40% after GnRHa and 17.8% after
mifepristone [64].
Asoprisnil (5, 10 or 25 mg) given orally, once daily
for 12 weeks reduced the uterine volume as well as
the volume of the largest leiomyoma in a dose-
dependant manner. At 10 and 25 mg, it suppressed
pelvis pressure after 12-weeks treatment in contrast
to placebo, which was inactive. No decrease of
plasma estradiol or increase of cortisol was observed.
This treatment is well tolerated and reduces sig-
nificantly both duration and intensity of uterine
bleeding in a dose-dependant manner [70].
Treatment of endometriosis
Endometriosis is an estrogen-dependent disease due
to ectopic endometrium. It causes pelvic pain,
dyspareunia, dysmenorrhoea and infertility [71].
Pelvic pain is the result of a local inflammatory
reaction and up-regulation of cyclooxygenase
(COX)- 2. The use of COX-2 inhibitors is therefore
an effective symptomatic option [72]. Use of
therapeutic agents, which hinder endometriosis, is
limited by their side effects. GnRHa and GnRH
antagonists use results in a hypo estrogenic state with
hot flushes and bone loss, which limits the treatment
duration. Progestins, the other therapeutic option,
can induce bloating, breakthrough bleeding, mood
changes, acne, hirsutism that can alter therapeutic
compliance [73].
Inhibiting ectopic endometrium proliferation with-
out inducing estrogen deprivation would be an
important goal for the treatment of endometriosis.
In this indication, SPRMs may ultimately have an
important place. Mifepristone inhibits endometrial
cells proliferation by activating the nuclear factor-
kappa B signalling pathway [74]. Mifepristone also
promotes apoptosis in human endometrial cells by
over expression of Bax, the apoptosis promoting gene
and by down-regulation of the anti-apoptosis gene
Bcl2 [75].
Mifepristone (5 or 50 mg/day for 6 months or
100 mg/day for 3 months) improved the clinical
symptoms associated to endometriosis [75]. The
50 mg daily dose elicited a mean 55% regression of
visible endometriosis after 6 months of treatment.
Asoprisnil, which inhibits endometrial prolifera-
tion and prostaglandin synthesis [76], was studied in
subjects with a laparoscopic diagnosis of endome-
triosis at 5, 10 and 25 mg (versus placebo) for 12
weeks. All doses were significantly effective on pain
scores, at all treatment months compared with
placebo [70]. The effect on bleeding pattern was
also dose-dependent. Asoprisnil was well tolerated in
short-term studies, and no serious adverse event was
reported during treatment period and follow-up [76].
Conclusion
PAs and SPRMs are largely used for fertility control.
They have proven efficacy for abortion and EC. In
long-term contraception, they offer an estrogen-free
contraception with a better bleeding pattern than that
associated with progestins. Because they control the
growth of leiomyoma and endometrial cells without
inducing an hypo estrogenic state, their use in
endometriosis and symptomatic leiomyomata could
be promising. Large Phase III trials in patients with
menorrhagia associated with uterine fibroids are in
progress. Efficacy and safety of long-term adminis-
tration for management of uterine bleeding, endo-
metriosis and uterine fibroids are actively studied.
On the basis of their pharmacological and clinical
features, SPRMs could have in the future important
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Some of them such as asoprisnil and mifepristone
inhibit mammary epithelial cells proliferation, in
animal models. They might have a key role in the
prevention and treatment of benign and malignant
breast pathologies.
Some concern appeared initially about endome-
trial safety because hyperplasia was described on
mifepristone treatment. Endometrial biopsies from
patients treated with different SPRMs were recently
reviewed by a panel of experienced pathologists to
develop consensus observations and recommenda-
tions [77]. New terminology and diagnostic criteria
were defined as PRM- associated endometrial
changes. These observations are reassuring as no
pre-malignant lesions were seen. However, long-
term follow-up is necessary to better define the
specific role of this new class of agents as well as of
their regimen of administration.
Declaration of interest: The authors report no
conflicts of interest. The authors alone are respon-
sible for the content and writing of the paper.6
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